Assessing and Treating Vulnerable Populations for Depressive Disorders

For this assignment, you will develop a patient medication guide for treatment of depressive disorders in a vulnerable population (your choice for one vulnerable patient population to choose from: children, adolescents, older adults, dementia patients, pregnant women or one not listed of your choice!). Be sure to use language appropriate for your audience (patient, caregiver, parent, etc.). You will include non-copyright images and/or information tables to make your patient medication guide interesting and appealing. Limit your patient medication guide to 5 pages. You will create this guide as an assignment; therefore, a title page, introduction, conclusion, and reference page are required. You must include a minimum of 3 scholarly supporting resources outside of your course provided resources.
In your patient guide, include discussion on the following:
• Depressive disorder causes and symptoms
• How depression is diagnosed for the vulnerable population of your choice, why is this population considered vulnerable
• Medication treatment options including risk vs benefits; side effects; FDA approvals for the vulnerable population of your choice
• Medication considerations of medication examples prescribed (see last bullet item)
• What is important to monitor in terms of labs, comorbid medical issues with why important for monitoring
• Special Considerations (you must be specific, not general and address at least one for EACH category; you must demonstrate critical thinking beyond basics of HIPPA and informed consent!): legal considerations, ethical considerations, cultural considerations, social determinants of health
• Where to follow up in your local community for further information
• Provide 3 examples of how to write a proper prescription that you would provide to the patient or transmit to the pharmacy.
RESOURCES

Required Readings
• Baek, J. H., Nierenberg, A. A., & Fava, M. (2016). Pharmacological approaches to treatment-resistant depression. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics (pp. 44–47). Elsevier.
• Fava, M., & Papakostas, G. I. (2016). Antidepressants. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics (pp. 27–43). Elsevier.
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.)Links to an external site.. https://doi.org/10.1176/appi.books.9780890425596
• Howland, R. H. (2008a). Sequenced Treatment Alternatives to Relieve Depression (STARD). Part 1: Study design. Journal of Psychosocial Nursing and Mental Health ServicesLinks to an external site., 46(9), 21–24. https://doi.org/10.3928/02793695-20080901-06 • Howland, R. H. (2008b). Sequenced Treatment Alternatives to Relieve Depression (STARD). Part 2: Study outcomes. Journal of Psychosocial Nursing and Mental Health ServicesLinks to an external site., 46(10), 21–24. https://doi.org/10.3928/02793695-20081001-05
• Lorberg, B., Davico, C., Martsenkovskyi, D., & Vitiello, B. (2019). Principles in using psychotropic medication in children and adolescents. In J. M. Rey & A. Martin (Eds.), IACAPAP e-textbook of child and adolescent mental healthLinks to an external site.. https://iacapap.org/_Resources/Persistent/45bdffb25befc353c9f61988e82105029504ab85/A.7-Psychopharmacology-2019.1.pdf
• Magellan Health. (2013). Appropriate use of psychotropic drugs in children and adolescents: A clinical monographLinks to an external site.. http://www.magellanhealth.com/media/445492/magellan-psychotropicdrugs-0203141.pdf
• Poznanski, E. O., & Mokros, H. B. (1996). Child depression rating scale—RevisedLinks to an external site.. Western Psychological Services.
• Rao, U. (2013). Biomarkers in pediatric depression. Depression & AnxietyLinks to an external site., 30(9), 787–791. https://doi.org/10.1002/da.22171
• Yasuda, S. U., Zhang, L. & Huang, S.-M. (2008). The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies. Clinical Pharmacology & TherapeuticsLinks to an external site., 84(3), 417–423. https://web.archive.org/web/20170809004704/https://www.fda.gov/downloads/Drugs/ScienceResearch/…/UCM085502.pdf
Medication Resources
• U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugsLinks to an external site.. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Review the following medications:
• amitriptyline
• bupropion
• citalopram
• clomipramine
• desipramine
• desvenlafaxine
• doxepin
• duloxetine
• escitalopram
• fluoxetine
• fluvoxamine • imipramine
• ketamine
• mirtazapine
• nortriptyline
• paroxetine
• selegiline
• sertraline
• trazodone
• venlafaxine
• vilazodone
• vortioxetine

Required Media
• Doc Snipes. (2022, April 13). Major depressive disorders in the DSM 5 TRLinks to an external site. [Video]. YouTube. https://www.youtube.com/watch?v=q5Npw03I0t8
Note: The approximate length of this media piece is 59 minutes.
• Psych Hub. (2020, October 5). Social determinants of healthLinks to an external site. [Video]. YouTube. https://www.youtube.com/watch?v=17jeXGbKlTQ
Note: The approximate length of this media piece is 4 minutes.

Optional Resources
• El Marroun, H., White, T., Verhulst, F., & Tiemeier, H. (2014). Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: A systematic review. European Child & Adolescent PsychiatryLinks to an external site., 23(10), 973–992. https://doi.org/10.1007/s00787-014-0558-3
• Gordon, M. S., & Melvin, G. A. (2014). Do antidepressants make children and adolescents suicidal? Journal of Pediatrics and Child HealthLinks to an external site., 50(11), 847–854. https://doi.org/10.1111/jpc.12655
• Seedat, S. (2014). Controversies in the use of antidepressants in children and adolescents: A decade since the storm and where do we stand now? Journal of Child & Adolescent Mental HealthLinks to an external site., 26(2),
iii–v. https://doi.org/10.2989/17280583.2014.938497